Member Info for Faxandtheinfinit

I would like to think they aren’t in a rush until the fanfare is ready to take sareum to a multi billion pound pharmaceutical company IMO

It’s about time CPX had a chat with THEvBERKSHIRE HATHAWAY GROUP x

Yes I was hoping for more an immediate reaction to market but this is 100% a keeper. This will move when cpx beat Maxwell/Tesla in court case obviously ??

Yea I know the feeling KBundy a person I didn’t know seven years ago last Thursday shown signs of mad cow’s disease unfortunately he only ate chicken but died anyway

Plus I would just like to add if PC pulls off CS and commercialisation becomes apparent then the floats gates will open be happy will your choice of investment. To read nobody has to listen lol half wit I have non at all thanks

Claire I don’t usually respond but here goes. 1.4 million tons Pozzolan and perlite CS project ready to mine exciting.. CS expansion just say the same?? Other future Pozzolan mapped ready to drill no estimates but just say the same as CS.. other than that look at AIM stocks and the things MMs will do to get your shares. One other I hold 3.4 billion shares in issue went up to 10p no commercialisation just sentiment and possible future projection. It is not as clear as 1 +1 = 2 sometimes 1+1 = 10.. anyway this is not an RNS and to early for gin. Yes remember gold silver but I like the environmentally friendly stuff Bonjour!!!

Commercialisation is a big word with regards to AIM stocks I’m looking for 10p short term 50p long term. Just to add am an investor and l always look on the bright side of life!

Good… so understood from 1st March Institutional investors galore can’t wait to under stand that??? If they invest at market value is there a difference from now till then not quite sure there is but wtfdik??? Cancer pill lm loving that

IMO news of institutional investment is long over due and news from our brokers…is PEEL HUNT still our joint corporate broker??????

With broker forecast of 15p and results 23rd you would of thought this would have started to stir by now…?

Is the sleeping giant waking up???? Some large trades cool x

HELLO PEEL HUNT just letting you know you can have a couple of a million of my shares on the way to 50p in todays money. Thanks xxxxxxxx

Become a working class hero keep hold those golden tickets. RNSs CAN’T LIE

16th Dec RNS
RNS
16th Dec
AGM STATEMENT.

Bit I like

WE ARE CONFIDENT THAT THE STUDIES HAVE MET THEIR OBJECTIVES

SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

News would be good about now come on PC you know you want to be the green king of construction.

16th Dec RNS
RNS
16th Dec
AGM STATEMENT.

Bit I like

WE ARE CONFIDENT THAT THE STUDIES HAVE MET THEIR OBJECTIVES

SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

16th Dec RNS
RNS
16th Dec
AGM STATEMENT.

Bit I like

WE ARE CONFIDENT THAT THE STUDIES HAVE MET THEIR OBJECTIVES

SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

16th Dec RNS
RNS
16th Dec
AGM STATEMENT.

Bit I like

WE ARE CONFIDENT THAT THE STUDIES HAVE MET THEIR OBJECTIVES

SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

I suppose it’s lucky the consolidation isn’t on the 29th????!!!

RNS
16th Dec
AGM STATEMENT.

Bit I like

WE ARE CONFIDENT THAT THE STUDIES HAVE MET THEIR OBJECTIVES

SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.

Thoth2 you asked many moons ago if there was any other companies worth investing in. IMO take a look at CAP-xx. super capacitors IP ect